News

Vaccine vs placental malaria
Enlarge image

FundingEUGermanyFranceDenmark

Vaccine vs placental malaria

04.03.2013 - Researchers from the PlacMalVac project have bagged €6m from the EU to start clinical trials of a placental malaria vaccine.

Pregnant women are particularly vulnerable to malaria, due to a particular type of pathology. Their infected blood cells clump together in the placenta, leading to growth retardation and preterm delivery, which in turn cause higher infant mortality. For the first time, a EU consortium of 5 partners led by University of Copenhagen will now begin clinical trials with a vaccine that blocks that blood aggregation in placenta-associated malaria (PAM). It targets the var2CSA protein, which causes aggregation of Plasmodium falciparum-infected erythrocytes by adhesion to the primary placental adherence receptor, chondroitin sulphate A (CSA), present in the placental intervillous blood spaces. Infected mice not carrying var2CSA do not show the PAM-associated effects.

“This will be the first clinical trial using the parasite antigens", said project coordinator Thor G. Theander from the University of Copenhagen. "The vaccine attempts not to eliminate the infection but to eliminate the disease. At Centre for Medical Parasitology we are all thrilled to have this opportunity. It marks an intermediate highpoint of many years of committed research.”

In previous projects supported by the Danish National Advanced Technology Foundation, Theander's team defined a smaller region of multi-domain protein var2CSA. Overall they identified three antigenic regions within it that are crucial for blocking PAM in rats. "We managed proof of concept for the malaria vaccine and we are currently addressing manufacturability of the vaccine. The funding from EU FP7 will enable us to continue the development including upstream and downstream process development, GMP production, Phase Ia and Ib human clinical trials, as well as preparations for Phase II clinical trials."

Theander now heads the EU consortium, which includes University of Copenhagen, ExpreS2ion Biotechnologies (Denmark), Institut de Recherche pour le Développement (France), Université d'Abomey-Calavi (Benin), University of Tübingen and the European Vaccine Initiative (EVI). The EVI has mobilised further €10m for the development of PAM vaccines within the projects PRIMALVAC and PAMCPH.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/vaccine-vs-placental-malaria.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.78 EUR0.00%
  • ACTELION114.40 CHF0.00%
  • ADDEX3.20 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.78 EUR0.00%
  • ACTELION114.40 CHF0.00%

TOP

  • WILEX3.43 EUR74.1%
  • BASILEA122.20 CHF16.4%
  • ACTELION114.40 CHF12.2%

FLOP

  • SANTHERA94.55 CHF-13.9%
  • 4SC0.78 EUR-10.3%
  • BIOFRONTERA1.84 EUR-6.6%

TOP

  • SANTHERA94.55 CHF2330.6%
  • WILEX3.43 EUR481.4%
  • FORMYCON16.70 EUR106.7%

FLOP

  • CYTOS0.34 CHF-88.7%
  • MOLOGEN5.38 EUR-55.7%
  • BIOFRONTERA1.84 EUR-53.3%

No liability assumed, Date: 01.03.2015